Researchers from Qualigen Therapeutics Inc. and University of Louisville presented the discovery and preclinical evaluation of a novel pan-RAS inhibitor...

Procalcitonin (PCT) has gained evidence as a potential biomarker during parasitic infection-driven sepsis, as it has been shown that PCT...

Reduced expression of nuclear factor erythroid 2-related factor 2 (Nrf2) is observed in humans and animal models of Alzheimer’s disease (AD), with its activation being a promising therapeutic approach.

RNA binding fox-1 homologue 1 (RBFOX1) is a splicing factor that regulates alternative splicing and modulates the expression of several genes involved in brain development, and it is among the top identified loci related to psychiatric disorders. 

Rational drug design based on EPI-X4, endogenous antagonist of C-X-C motif chemokine receptor (CXCR4), led to the identification of optimized analogues named JMF-01 to JMF-07, which demonstrated increased antagonistic activity.

The British Columbia Cancer Agency recently discussed their research efforts toward the discovery of new radiotherapeutic agents for the treatment of prostate cancer.

At the Saturday, Oct. 22 session, ‘Basic Science: Correlates of protection, immune response and the host-microbe interaction,’ of the IDWeek 2022 infectious disease conference, moderator Luiz Bermudez, professor at Oregon State University, introduced the latest advances to prevent infections with Treponema pallidum during neurosyphilis (NS), Staphylococcus aureus and osteomyelitis, and Mycobacterium tuberculosis during influenza.